Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
INTERVENTIONAL
Inicio: 24 de jun de 2024
ID: NCT06393374
Completado
Fase 2
ClinicalTrials.gov
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
INTERVENTIONAL
Inicio: 1 de jul de 2012
ID: NCT01677455
Completado
Fase 2
ClinicalTrials.gov
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
INTERVENTIONAL
Inicio: 1 de oct de 2003
ID: NCT00229697
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
INTERVENTIONAL
Inicio: 10 de jun de 2025
ID: NCT06340568
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
INTERVENTIONAL
Inicio: 7 de ago de 2012
ID: NCT01610284
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
INTERVENTIONAL
Inicio: 8 de may de 2023
ID: NCT05840211
Completado
Fase 3
ClinicalTrials.gov
Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer
INTERVENTIONAL
Inicio: 1 de jun de 2014
ID: NCT02162667
Activo, no recluta
Fase 3
ClinicalTrials.gov
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
INTERVENTIONAL
Inicio: 11 de mar de 2022
ID: NCT05169567
Desconocido
ClinicalTrials.gov
Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer
OBSERVATIONAL
Inicio: 1 de jun de 2023
ID: NCT05070884
Activo, no recluta
Fase 3
ClinicalTrials.gov
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
INTERVENTIONAL
Inicio: 4 de oct de 2021
ID: NCT04975308
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
INTERVENTIONAL
Inicio: 1 de jun de 2006
ID: NCT00329693
Completado
Fase 2
ClinicalTrials.gov
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
INTERVENTIONAL
Inicio: 1 de jun de 2010
ID: NCT01068704
Completado
Fase 2
ClinicalTrials.gov
Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01606072
Completado
Fase 2
ClinicalTrials.gov
An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
INTERVENTIONAL
Inicio: 1 de nov de 2003
ID: NCT00062686
Activo, no recluta
ClinicalTrials.gov
Association of Axillary Lymph Node Dissection With Oncological Outcomes in Patients With Residual Micrometastases After Neoadjuvant Chemotherapy: The OPBC-07/microNAC Study
OBSERVATIONAL
Inicio: 15 de may de 2024
ID: NCT06529302
Completado
Fase 3
ClinicalTrials.gov
A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer
INTERVENTIONAL
Inicio: 17 de may de 2012
ID: NCT01566721
Desconocido
ClinicalTrials.gov
Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases
OBSERVATIONAL
Inicio: 1 de ene de 2016
ID: NCT03210298
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 27 de nov de 2020
ID: NCT04576455
Reclutando
ClinicalTrials.gov
Effect of Consumption of a Dairy Product Designed for Pregnant and Lactating Women on the Composition of Human Milk. A Quasi-experimental Study in a Vulnerable Population
INTERVENTIONAL
Inicio: 1 de ago de 2025
ID: NCT07173881
Terminado
Fase 3
ClinicalTrials.gov
An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 30 de may de 2019
ID: NCT03786094
Anterior
1
...
10
11
12
...
434
Siguiente
Filtros